Gilead's hep C combo Harvoni hoves into EU view
This article was originally published in Scrip
Gilead's highly anticipated fixed-dose combination hepatitis C therapy Harvoni (sofosbuvir/ledipasvir 400 mg / 90 mg, film coated tablet) is one step closer to the EU market following a positive opinion from the EU's CHMP.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.